Potential interaction between MonaVie Active and Warfarin

American Journal of Health-System Pharmacy

Volumn 67, Issue 2, 2010, Pages 107-108

  Katcher, Summer ^a   Leung, Simon ^a  

^a MEMORIAL REGIONAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FATTY ACID ESTER; GLUCOSAMINE; MONAVIE ACTIVE; PHYTOMENADIONE; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING; DIETARY INTAKE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTE AGGREGATION;

EID: 75149163615     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090542     Document Type: Letter

References (13)

1. MonaVie. Answers to your product questions. www.monavie.com/Web/US/en/ faq.dhtml (accessed 2009 Oct 20).
2. CalComp Nutrition. MonaVie ingredients. www.calcomp-nutrition.com/ monavie-ingredients.html (accessed 2009 Oct 20).
3. Franco V, Polanczyk CA, Clausell N et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004; 116:651-6.
4. Sconce E, Khan T, Mason J et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005; 93:872-5.
5. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev. 1999; 57(9 pt 1):288-96.
6. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):160S-98S.
7. Rozenfeld V, Crain JL, Callahan AK. Possible augmentation of warfarin effect by glucosamine-chondroitin. Am J Health-Syst Pharm. 2004; 61:306-7.
8. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmcotherapy. 2008; 28:540-8.
9. Chan EJ, Cho L. What can we expect from omega-3 fatty acids? Cleve Clin J Med. 2009; 76:245-51.
10. Jalili M, Dehpour AR. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids. Arch Med Res. 2007; 38:901-4.
11. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy. 2007; 27:152-60.
12. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004; 38:50-2.
13. Nieuwenhuys CM, Béguin S, Offermans RF et al. Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty acids with unchanged platelet activation in rats. Arterioscler Thromb Vasc Biol. 1998; 18:1480-9.